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Abstract
Background: This pilot trial aimed to study the feasibility and effects on quality of life (QOL) and well-being of
short-term fasting (STF) during chemotherapy in patients with gynecological cancer.
Methods: In an individually-randomized cross-over trial patients with gynecological cancer, 4 to 6 planned
chemotherapy cycles were included. Thirty-four patients were randomized to STF in the first half of
chemotherapies followed by normocaloric diet (group A;n = 18) or vice versa (group B;n = 16). Fasting
started 36 h before and ended 24 h after chemotherapy (60 h-fasting period). QOL was assessed by the
FACIT-measurement system.
Results: The chemotherapy-induced reduction of QOL was less than the Minimally Important Difference (MID; FACT-G = 5)
with STF but greater than the MID for non-fasted periods. The mean chemotherapy-induced deterioration of total FACIT-F
was 10.4 ± 5.3 for fasted and 27.0 ± 6.3 for non-fasted cycles in group A and 14.1 ± 5.6 for non-fasted and 11.0 ± 5.6 for
fasted cycles in group B. There were no serious adverse effects.
Conclusion: STF during chemotherapy is well tolerated and appears to improve QOL and fatigue during chemotherapy.
Larger studies should prove the effect of STF as an adjunct to chemotherapy.
Trial registration: This trial was registered at clinicaltrials.gov: NCT01954836.
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Background
Experimentally, short-term fasting (STF) protects healthy
cells against the adverse effects of chemotherapy while
making tumor cells more vulnerable to it [1]. An increas-
ing body of evidence from basic research points to benefi-
cial effects of intermittent and periodic fasting in chronic
disease [2–7]. Fasting promotes pronounced changes in
metabolic pathways and cellular processes such as stress
response (hormesis), autophagy and decreases IGF-1 that
affects other factors as Akt, Ras and mammalian target of
rapamycin (mTOR) to downregulate cell growth and pro-
liferation [8]. In primates and in rodents caloric restriction
and intermittent fasting are associated with reduced
cancer risk [9, 10]. Chemotherapy is a mainstay in the
treatment of malignant tumors, but frequently limited by
its toxicity. Recently it has been shown, that the effects of
fasting on susceptibility to chemotherapy differ between
normal cells and cancer cells, a phenomenon described as
differential stress resistance (DSR) [11, 12]. Experimental
data indicate that fasting states may promote the protection
of normal cells, but not cancer cells during chemotherapy, as
oncogenic pathways inhibit the stress resistance. In healthy
cells pronounced metabolic and gene expression changes are
induced by fasting, including upregulation of DNA repair
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pathways and antioxidants, partly mediated by the shut
down of pathways such as IGF-1/Akt and mTOR [13].
As weight loss may negatively affect the prognosis of
cancer patients with cancer, short- term fasting (STF),
which is not related to long-term weight loss and its ad-
verse effects has been introduced in basic research as a
potential add-on treatment during chemotherapy [14].
So far, experimental data consistently show that the
combination of short-term fasting cycles with chemo-
therapy is effective in enhancing chemotherapeutic toler-
ability and efficacy and thus has high translational
potential [1]. In a first case series on 10 patients with
various types of cancer STF was found to be feasible and
reduced severity of chemotherapy-induced side effects.
[8]. In a recent randomized pilot-study 13 women with
HER2-negative breast cancer receiving neo-adjuvant
chemotherapy were randomized to STF during chemo-
therapy or to eat a common healthy diet. Fasting
reduced the hematological toxicity of chemotherapy and
induced a faster recovery of DNA damage [12]. The
present pilot study was designed to assess the effect of a
60 h-STF on quality of life (QOL) in patients with
gynecological cancer under chemotherapy. Based on the
experimental evidence we hypothesized that fasting
increases QOL and reduces fatigue during chemotherapy
compared to standard nutrition [15]. By means of an
explorative cross-over design we compared QOL, general
well-being and fatigue across all fasted chemotherapy cycles
versus all chemotherapy cycles with normocaloric diet.
Methods
This study was designed as a randomized, individually
controlled cross-over trial. The study design was chosen
on the background of the anticipated heterogeneity of
the study population and chemotherapy protocols. All
study participants gave their written informed consent.
The study protocol was reviewed and approved by the
Ethics Committee of the Charité-University Medical
Center, Berlin (EA4/088/13). Patients were enrolled be-
tween November 2013 and March 2015; interventions
and follow-up were completed by August, 2015. Study
procedures and data collection were carried out at the
outpatient department of the Charité -University Berlin
at Immanuel Krankenhaus Berlin.
Study procedures
Patients were referred by three gynecological hospital
departments, two centers for breast cancer care and the
Charité European Center for ovarian cancer. Potential
participants were screened for eligibility during an ap-
pointment at the study center, and eligible candidates
were scheduled for an enrollment appointment. Each
eligible participant was randomly assigned to two different
sequences of nutrition during the scheduled chemotherapy.
Group A was randomized to a STF of 60 h during the first
three of scheduled 6 chemotherapies (36 h before to 24 h
after the chemotherapy) followed by normocaloric nutrition
during the following 3 chemotherapies. Group B was
allocated to a vice versa sequence of nutrition. Between
the chemotherapy cycles all patients were advised to
follow their common diet. All patients received an ap-
proximate 1 h counselling by dieticians experienced in
fasting treatments.
All measurements were performed baseline and 8 days
after each chemotherapy cycle. Subjects height/body
weight were measured following a standardized protocol.
For assessment of QOL, general well-being and fatigue
validated inventories were used. Adverse effects were
assessed by two 2 interviews during and at the end of
fasting and by means of a diary.
Patients
All women had a confirmed diagnosis of breast cancer or
ovarian cancer and a scheduled chemotherapy. Eligibility
criteria included age ≥ 18 years; BMI ≥ 19 kg/m2; WHO
performance status 0–2; anticipated life expectancy of >
3 months; Exclusion criteria included: Type-1 diabetes or
intensified insulin treatment; myocardial infarction, stroke
or pulmonary embolism within the last 3 months; un-
stable heart disease; renal failure, history of eating dis-
order; dementia, psychosis, impaired physical mobility.
One hundred twenty-one patients were screened, 50
patients fulfilled the inclusion criteria and were recruited
to the study. The patient flow chart is given in Fig. 1.
One patient cancelled the complete chemotherapy treat-
ments initially. Although STF was generally well toler-
ated, four patients withdrew from STF after having
experienced minor side effects of STF like headache
(two cases), hyperventilation during first chemotherapy
(one case) and general subjective weakness (one case).
One patient reported an aversion to fasting nutrients.
Thus, in total 5 patients (10%) dropped out related to
the fasting intervention. Two patients withdrew from
the study because of personal reasons (family problems),
each in the diet phase. Eight subjects could not be
assessed for the follow-ups as a result of non-adherence
with the study because of time restrictions and complete
unwillingness to fill out further study documents (three
in the fasting phases, five in the diet phases). These
drop-outs were not related to any adverse effects of the
study interventions as assessed by telephone interviews.
A total of 34 patients with primary BC (n = 29), ad-
vanced BC (n = 1) and OC (n = 4) were analysed.
Interventions
All patients received standard oncological care as deter-
mined by their individual requirements. Patients in both
groups were advised to maintain their regular physical
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activity and to abstain from other new integrative or
supportive treatments during the study period.
Chemotherapeutic drugs and standard therapy
Chemotherapeutic drugs used in this study were taxanes
(docetaxel (D), paclitaxel (T)), platinum agents (carboplatin
(P), cyclophosphamide (C), anthracyclines (epirubicin (E),
doxorubicin (A), methotrexatate (M), fluorouracil (F), the
IgG1 antibody bevacizumab (Avastin) and for patients with
HER2/neu overexpression pertuzumab or trastuzumab.
These were given in various standard combinations accord-
ing to guideline-based treatment protocols. For patients
with breast cancer we had the following regimens: EC,
FEC-D; FEC-D + trastuzumab, AC-T,EC-T,TAC and D+
pertuzumab+ trastuzumab. For patients with ovarian can-
cer we used: P mono, P + T, EC-T + P and P +T+ bevacizu-
mab. Standard antiemetics and medication to prevent
hypersensitivity reactions were administered, including
dexamethasone and 5HT3 inhibitors.
Fasting intervention
All patients received individual dietary counselling ac-
cording to their individual needs in order to correctly
perform the fasting program and the normocaloric diet.
The fasting program was adapted to the established ap-
proach of modified fasting used in our hospital for many
years and evaluated in studies in patients with rheumatic
diseases and chronic pain [16]. The fasting period
started 36 h before chemotherapy and ended 24 h after
the end of the chemotherapy resulting in a total fasting
period of 60 h. During the fasting period subjects re-
ceived unrestricted amounts of water, herbal tea, 2x100cl
vegetable juice and small standardized quantities of light
vegetable broth with a maximum total daily energy
Fig. 1 Study flow chart
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intake of 350 kcal. Compliance with the fasting regimen
was assessed by telephone calls and personal interviews
at the end of the chemotherapy cycles.
Standard nutrition period
All patients were advised to follow a normocaloric
Mediterranean diet throughout this study phase in-
cluding the chemotherapy days.
Randomization
Patients were randomly allocated to treatment groups
(block-randomization with randomly varying block sizes
(SAS/Base® statistical software (SAS/Base® statistical soft-
ware)). For each patient sealed, sequentially numbered
envelopes containing treatment assignments were pre-
pared. Allocation of treatment was not blinded.
Inventories for outcome assessment
For measuring health-related QOL we used the functional
assessment of chronic illness therapy (FACIT©) measure-
ment system. The Functional Assessment of Cancer
Therapy-General (FACT-G©) forms the generic core
questionnaire of all FACIT© scales. The FACIT© scales
are constructed to complement the FACT-G© scale by ad-
dressing relevant disease-, treatment-, or condition-related
issues not already covered in the general questionnaire.
The Trial Outcome Index (TOI) is a measure of physical
aspects of QOL. It is the sum of the FACT-G subscales of
physical well-being (PWB), functional well-being (FWB),
and any FACIT© disease-, treatment-, or condition-
specific scale. For additional concerns we used the FACIT-
F©, a 13-item questionnaire that assesses self-reported fa-
tigue and its impact upon daily activities. Altogether we
obtained 8 different scales and subscale scores: the sub-
scales PWB, EWB, SWB, FWB as compounds of the
FACT-G© scale (27 items); the additional subscale
FACIT-F© (13 items); the TOI-FACIT-F© (27 items) and
the total FACIT-F© scale as union of the FACT-G© and
FACIT-F© scales (40 items).
Statistical analysis
This randomized cross-over pilot study aimed to give
first insight into QOL and tolerability to chemotherapy
in breast or ovarian cancer patients with STF versus nor-
mocaloric diet during chemotherapy. As a pilot study it
aimed to enable the design of a further confirmatory
trial that is anticipated.
All FACIT© scales were scored with a higher score
indicating better well-being. Here, we reversed re-
sponse scores on negatively phrased questions, then
added the item responses. The scores were obtained
in accordance with the formula that had been previ-
ously established by the FACIT© system. In cases
where individual questions were skipped, scores were
prorated using the average of the other answers in
the subscale (prorated subscale score = [sum of the
item scores]*[N of items in subscale]/[N of items an-
swered]) as long as more than 50% of the items were an-
swered (minimum of 4 items for the subscales). The
FACT-G score was considered appropriate as long as at
least 22 of 27 FACT-G items were completed (≥80%).
Inter-subscale correlations were computed using Pearson
correlation, and the reliability of the internal consistency
for all scales were assessed by computing Cronbach’s
alpha. When Cronbach’s alpha exceeded 0.90, the scale
was considered to have sufficient precision for individual
classification or diagnosis. MIDs of fasting and non-
fasting groups were used to find clinically meaningful im-
provements in symptoms and to aid the interpretation of
group differences and changes in QOL over time. A MID
for scores of scales is defined by the “smallest change in a
score in the domain of interest that patients perceive as
important, either beneficial or harmful, and that would
lead the clinician to consider a change in the patient’s
management” [17]. MID values over 3–7 (mean 5) for
FACT-G© and over 3–4 for Fatigue subscale and 6 for
Total FACT-F were considered significant.
The sample size was calculated for the group A starting
with STF assuming an equivalence margin of 5 i.e. the
MID of FACT-G, a true difference of 7 and a standard de-
viation of 3. A sample size of 16 achieves a power of 82%
with a significance level of 0.05. Assuming the same con-
dition for the group B we obtain 32 patients as minimum.
Continuous variables with a normal distribution
were expressed as mean value and standard deviation.
Normality was tested with the Shapiro–Wilks test.
Statistical comparison of baseline characteristics and
outcomes was performed using the × 2 test with Yates
correction or the Fisher exact test, when appropriate,
for categorical variables. For continuous variables we
used the two-tailed Student’s t-test respectively the
independent-samples Mann-Whitney U test in order
to test the null hypothesis that the distribution of a
variable is the same across the groups A and B.
Calculations were performed with NCSS (Version 10),
R (version 3.1.0) and IBM SPSS Statistics for Windows
(Version 22.0. Armonk, NY: IBM Corp).
Results
The median age of the 34 patients was 51y (range 28-69y).
Eighteen patients started with fasting during the first half
of chemotherapy cycles (group A) whereas the other 16
patients (group B) started with normal diet (Table 1).
Fasting was safe and all reported side effects were of
low grade and at a level that did not interfere with daily
activities. Minor adverse effects during all cycles, and
mainly during the first STF cycle, included headache
(5×), hunger (5×), slight nausea after intake of broth or
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juices (11×) and one orthostatic reaction. There was one
wound infection, unrelated to fasting. Regarding toler-
ability of chemotherapy there were no common toxicity
criteria grade III/IV adverse events documented.
Changes in body weight/body mass index
Weight gain is a common problem for breast/ovarian
cancer patients treated with chemotherapy and in par-
ticular with anthracyclines+taxanes [18]. In this trial
there were no significant (p > 0.3) changes in weight.
Mean body weight (BMI) of the patients in group A was
73 kg (26.1) at the beginning and 72.3 kg (25.8) at the
end of the trial. For group B the corresponding values
are 67.9 kg (23.7) and 68.5 kg (24.2).
Throughout all chemotherapy cycles of the 34 patients
we documented 102 cycles fasted and 74 cycles on nor-
mocaloric diet. The numerical difference between fasted
and non-fasted cycles is a result of 5 patients who didn’t
want to switch to normocaloric diet after having fasted
the first 3 cycles. Compliance with the fasting protocol,
as checked by diaries, telephone calls and interviews ap-
peared good.
Table 1 Legend: Baseline characteristics for both groups. Group A: Fasting for the first half of cycles of chemotherapy and eating a
normocaloric diet for the second half of cycles; Group B: Eating a normocaloric diet for the first half of cycles of chemotherapy and
fasting for the second half of cycles


















Menopausal status premenopausal 24 13 (72.2) 11 (68.7) 0.824
postmenopausal 10 5 (27.8) 5 (31.3)
Tumor entity primary breast cancer 25 (73.5) 12 (66.7) 13 (81.3) 0.691
advanced breast cancer 5 (14.7) 3 (16.7) 2 (12.5)
ovarian cancer 3 (8.8) 2 (11.1) 1 (6.3)
advanced ovarian cancer 1 (2.9) 1 (5.6) 0 (0.0)
T-categories T0 1 (2.9) 0 (0.0) 1 (6.3) 0.323
T1 14 (41.2) 7 (38.9) 7 (43.8)
T2 13 (38.2) 9 (50.0) 4 (25.0)
T3 6 (17.6) 2 (11.1) 4 (25.0)
Nodal status pNx 1 (2.9) 1 (5.6) 0 (0.0) 0.434
pN0 16 (47.1) 7 (38.9) 9 (56.3)
pN1 17 (50.0) 10 (55.6) 7 (43.8)
Grading G1 1 (2.9) 1 (5.6) 0 (0.0) 0.298
G2 17 (50.0) 7 (38.9) 10 (62.5)
G3 16 (47.1) 10 (55.6) 6 (37.5)
Breast cancer intrinsic
subtypes (n = 30)
Luminal A 3 (10.0) 3 (20.0) 0 (0.0) 0.098
Luminal B / HER2- 11 (36.7) 4 (26.7) 7 (46.7)
Luminal B / HER2+ 4 (13.3) 2 (13.3) 2 (13.3)
triple negative 9 (30.0) 6 (40.0) 3 (20.0)
HER2 overexpressing 3 (10.0) 0 (0.0) 3 (20.0)
Therapy (breast cancer) CT 25 (83.3) 13 (86.7) 12 (80.0) 0.624
CT + Anti-HER2 5 (16.7) 2 (13.3) 3 (20.0)
Therapy (ovarian cancer) CT 3 (75.0) 3 (100.0) 0 (0.0) 0.046
CT + Anti-HER2 + Anti-VEGF 1 (25.0) 0 (0.0) 1 (100.0)
Body Mass Index normal (BMI ≤25) 19 (55.9) 9 (50.0) 10 (62.5) 0.364
overweight (BMI: 25–30) 13 (38.2) 7 (38.9) 6 (37.5)
obese (BMI > 30) 2 (5.9) 2 (11.1) 0 (0.0)
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Baseline
The means of the various scales and subscales were
worse for patients with ovarian cancer compared to pa-
tients with breast cancer at baseline (day 0, cycle 1) (OC
vs BC: FACT-G 66.8 (±21.7) vs 80.5 (±15.3); FACIT-F
33.5 (±10.3) vs 39.7 (±10.2); Total FACIT-F 100.3(±31.8)
vs 120.2 (±21.7)). The internal consistencies were excel-
lent for the various questionnaires: (Cronbach’s alpha:
α > 0.9). FACT-G (α = 0.91), FACIT-F (α = 0.96), TOI
FACIT-F (α = 0.97) and total FACIT-F (α = 0.96). There
were statistically no significant differences in FACT-G
respectively its subscales between both groups at base-
line except for social/family well-being p = 0.042).
Chemotherapy courses
We used a 2 × 2 crossover design AB|BA (A = SFT; B =
normocaloric diet) with cross-over at cycle 4. Five pa-
tients had a total of only four cycles of chemotherapy, so
we aligned the first two cycles to c1 and c2 and the sec-
ond two cycles to c4 and c5.
The mean values of all scales at day 0 (before chemo-
therapy) were not significantly different for group A and
B across the 6 cycles, i.e. the patients recovered within 3
weeks from each cycle of chemotherapy with respect to
QOL (Fig. 2a/b) Hence, there seemed to be no carryover
effects from SFT respectively normocaloric diet during
the first three cycles to the second period.
Change of QOL after chemotherapy
Within group A we found a statistically and clinically
significant beneficial effect of STF during chemotherapy
(cycles c1-c3) versus normocaloric diet (cycles c4-c6) on
QOL and fatigue. In group B fasted cycles (c4-c6) were not
associated with a significant reduction of chemotherapy-
induced QOL and fatigue compared to regular diet (c1-c3)
(Table 2).
When analysing changes of QOL within the fasted or
non-fasted periods by applying minimally important dif-
ferences (MID for FACT-G = 5) we found for patients in
group A within the first three fasted cycles a decrease of
FACT-G (mean = 3.0) that was less than the MID. Thus,
patients under STF did not perceive the change between
FACT-G at day 0 and day 8 after chemotherapy as im-
portant. In contrast, the change of QOL for patients of
a
b
Fig. 2 a: Pretest values at cycles (C1-C6) in FACIT-F(FS), FACIT-F, FACIT-F TOI, FACT-G, and Total FACIT-F, Group A, Day 0. b: Pretest values at cycles
(C1-C6) FACIT-F(FS), FACIT-F, FACIT-F TOI, FACT-G, and Total FACIT-F Group B, Day 0
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group A across the normocaloric diet cycles c4-c6 was
greater than the MID (mean 12.8.), these patients per-
ceived the chemotherapy-induced reduction of QOL as
important [Fig. 3a,d].
Accordingly, the mean differences (day0 – day 8) of
TOI FACIT-F of group A was 10.5 for first three cycles
and 25.1 for cycles 4–6. Patients who fasted within the
first three cycles had a clinically significantly lower dif-
ference of TOI FACIT-F compared to the same patients
during cycles 4–6 on a regular diet.
The mean differences of TOI FACIT-F of group B was
13.1 for first three cycles and 10.8 for cycles 4–6. Patients
who fasted within the first three cycles had a clinically sig-
nificantly lower difference of TOI FACIT-F compared to
the same patients during cycles 4–6 on a regular diet.
There was no significant difference between the mean dif-
ferences of TOI FACIT-F for group A and group B during
the fasting cycles (10.5 vs 10.8).
In group B we found no statistically significant differences
between the first 3 cycles and the second three cycles.
However, when analysing changes of QOL within the fasted
or non-fasted periods by applying MID we found an aver-
age of mean difference of FACT-G for the cycles with STF
of 4.6 and with normocaloric diet of 8.1 [Fig. 3b, c]. Thus,
again patients with normocaloric diet had a mean differ-
ence above the MID in that phase whereas with STF the
mean difference was 4.6 i.e. below the MID. Fig. 3a-d
summarizes the forest plots of the chemotherapy-induced
changes of FACT-G in each of the two dietary phases in
both groups.
In general, STF was very well accepted by the patients.
At the final consultation the majority of patients re-
ported better tolerance to chemotherapy with STF, the
patient general assessment of the effectiveness of STF
revealed “good” or “very good” for 28 patients, “moder-
ate” in 5 patient s and “no effect” in 1 patient. Thirty-
one patients declared that they would fast again during
chemotherapy, 3 patients declared that they would not
like to fast again during chemotherapy.
Discussion
This is the first clinical study to explore the effects of
STF on QOL, fatigue and wellbeing during chemother-
apy. Experimentally, STF has been documented to in-
duce profound changes in gene expression and cellular
metabolism that render normal cells more resistant to
oxidative stress and thus may confer benefit in the situ-
ation of cancer treatment by chemotherapy [11].
The present study included women with breast cancer
and ovarian cancer and used an intra-individual ran-
domized cross-over study design to balance for the het-
erogeneity in disease states and chemotherapy protocols.
STF with a period of 60 h did not induce weight loss
and was associated with only minor adverse effects that
Table 2 Mean and standard deviations for outcome parameters with mean group differences and 95%CI for FACT-G, FACIT-F, TOI
FACIT-F, and Total FACIT-F between cycles with fasting and regular diet of group A and B at day 8 after chemotherapy
Descriptives
Group Cycle N Mean Std.
Deviation










FACT-G Group A first half of a 4–6 cycle 52 71.1 18.7 65.9 76.3 9.2 0.041
second half of a 4–6 cycle 27 61.9 18.5 54.6 69.2
FACT-G Group B first half of a 4–6 cycle 46 76.0 17.2 70.9 81.1 2 0.576
second half ofa 4–6 cycle 47 74.0 17.6 68.8 79.2
FACIT-F (FS) Group A first half of a 4–6 cycle 52 33.9 13.4 30.2 37.6 9.1 0.006
second half of a 4–6 cycle 27 24.8 13.7 19.4 30.2
FACIT-F (FS) Group B first half of a 4–6 cycle 46 33.4 14.0 29.3 37.6 1.8 0.521
second half of a 4–6 cycle 47 31.7 12.6 28.0 35.4
FACIT-F TOI Group A first half of a 4–6 cycle 52 66 25 59 72.9 16.2 0.009
second half of a 4–6 cycle 27 49.8 26.4 39.4 60.3
FACIT-F TOI Group B first half of a 4–6 cycle 46 68.0 25.2 60.5 75.5 4.2 0.41
second half of a 4–6 cycle 47 63.8 23.9 56.8 70.8
FACIT-F Total Group A first half of a 4–6 cycle 52 105 30.4 96.6 113.5 18.3 0.013
second half of a 4–6 cycle 27 105 30.5 74.6 98.8
FACIT-F Total Group B first half of a 4–6 cycle 46 109.5 29.8 100.6 118.3 4.2 0.531
second half of a 4–6 cycle 47 105.7 28.3 97.3 114.0
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were rated as not meaningful by the patients and did not
interfere with daily activities.
In general, STF led to a better tolerance to chemother-
apy with less compromised QOL and reduced fatigue
within the 8 days after chemotherapy.
To date, there are only three previous reports in smaller
samples that evaluated the effects of STF during chemo-
therapy. In a first case series Safdie et al. described 10
cases in which patients with various malignancies had vol-
untarily fasted prior to and after chemotherapy with vari-
ous lengths of the fasting periods [8]. Six patients that
underwent chemotherapies with and without fasting re-
ported a reduction in fatigue, weakness, and some gastro-
intestinal side effects by fasting.
In a recent pilot study De Groot et al. investigated a 48 h
zero-calorie fasting during TAC chemotherapy in 13 women
with confirmed HER-2-negative stage II and III breast can-
cer. Beside metabolic, endocrine and hematologic parame-
ters, DNA damage in PBMCs was also assessed and side
effects were evaluated according to the Common termin-
ology Criteria for Adverse events (CTCAE). Two patients
withdrew from fasting after the third chemotherapy because
of clinical deterioration not related to fasting. Fasting was
safe and had beneficial effects on hematologic toxicity and
possibly on DNA damage in healthy cells (lymphocytes and
myeloid cells) [19].
In the third report, a recent uncontrolled dose- escalation
and feasibility study, Dorff et al. investigated 20 patients
with three different fasting periods (24, 48 and 72 h).
Sixteen of the patients were compliant with the fasting regi-
men (< 200 kcal/day). Fasting was found to be safe and
feasible for the cancer patients. There was also some pre-
liminary evidence of reduced DNA-damage evident in host
leukocytes after chemotherapy exposure for subjects who
fasted for 72 h compared to 24 h in this study [20].
Our results confirm the feasibility and tolerability of
STF accompanying chemotherapy and extend on these
findings by indicating a potential beneficial effect on
QOL, fatigue and well-being during cancer treatment. As
QOL is an increasingly appreciated treatment outcome
the present results appear to be of clinical relevance.
We did not find any evidence of malnutrition. Of note,
the safety of fasting prior to chemotherapy can only be
extrapolated to the selected population of oncology pa-
tients, as we excluded those with recent weight loss or a
BMI < 19.0 kg/m2.
a b
c d
Fig. 3 FACT-G Forest plot of mean difference. a) Group A (pretest – day 8, cycles c1-c3 = fasting). b) Group B (pretest – day 8 (cycles
c1-c3 = normocaloric). c) Group B (pretest(c4) – day 8, cycles c4-c6 = fasting) and d) Group A (pretest(c4) – day 8, cycles c4-c6 = normocaloric)
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Our study has several limitations. The most obvious
limitation is the small sample size within the context of
an explorative pilot study, which limits the power of the
study and precludes firm statistical conclusions. The sec-
ond limitation is the cross-over design with the known
bias of carry-over effects. However, we chose this design
on the background of the defined small sample size and
the respective likelihood of heterogeneous groups ruling
out sound comparison of chemotherapy cycles with
common randomization. Another limitation is due to
the positive reputation of fasting cures in Germany. As
such, participants in the study could be predisposed to-
wards fasting, thereby inducing a non-specific effect..
This could only be addressed with a double-blind ran-
domized study, which, however, is not feasible.
We aimed to include more patients with ovarian can-
cer, however, as these patients were frequently weakened
by surgery, had more frequently experienced previous
weight loss and were more often included in other clin-
ical trials, the options for study recruitment were lim-
ited. The heterogeneity of the studied population and its
treatments is a limitation for interpreting the results,
however it reflects the current complexity of applied
chemotherapies and reflects the external validity of the
results. Finally, there is a possibility of underreporting
and non-compliance with fasting, despite our encourage-
ment to all study subjects to honestly disclose all food
and beverages consumed during the fasting periods and
the monitoring by the nutritionists. Yet, as fasting is
widely established and positively reputed in Germany
and all participants received detailed information before
study inclusion about the fasting scheme we believe that
the reported good compliance reflects the true compli-
ance with the fasting protocol.
Of note, the beneficial effect of fasting on quality of
life was more pronounced group in A compared to
group B. There are several possible explanations for this
differential effect. First, despite randomization Group A
showed statistically nonsignificant but clinically relevant
greater impaired quality of life than group B at baseline.
This may have influenced the treatment response to fast-
ing. Second, it could be that fasting is more effective if it
prevents negative effects before they happen rather than
after they occur. Third, patients in group A could have
experienced more pronounced non-specific effects as
they fasted first. In contrast, patients in group B might have
decreased their negative expectation of the adverse effects
of chemotherapy in the first cycles thereby reducing non-
specific effects of the following fasting intervention.
Conclusion
Our study shows that STF during chemotherapy is feas-
ible and has beneficial effects on QOL, well-being and
fatigue. Larger randomized trials with confirmatory
study design are warranted to further evaluate this in-
novative treatment approach.
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